Financing channel feed – Endpoints News

Financing channel feed

Brent Saunders joins $100M Series C for a company out to be the BridgeBio of aging

4 years ago

Xilio Therapeutics goes public as biopharma IPOs rumble forward in Q4

4 years ago

A new Treg player emerges with $46M and backing from Takeda

4 years ago

Pfizer throws its weight behind LNP player eyeing mRNA treatments for CF, PCD

4 years ago

As AI continues to entice Big Pharma, a Carlyle-led drugmaker syndicate shells out $430M for cloud computing player

4 years ago

Ventyx sprints to Wall Street less than a year after emerging from stealth

4 years ago

Epidarex, Sofinnova double down on a parallel take on 3rd-gen CAR-T — aiming straight at ovarian cancer

4 years ago

A new Schrödinger-backed startup emerges from the scientist who mapped the first human GPCR

4 years ago

Sofinnova hauls in $548M to build and scale startups — as European VCs step up their biopharma game

4 years ago

Can an IDO/PD-L1 combo ever work? Novo-backed company spells out how in biotech's latest IPO filing

4 years ago

Crinetics spins out radiopharma efforts into a new company, highlighting the growing field's allure

4 years ago

Qiming-backed Abbisko makes $200M+ Hong Kong debut, as a SPAC and Agenus spinout also price on Nasdaq

4 years ago

Pharma veterans regroup with $50M and a plan to discover new multi-specifics

4 years ago

In the packed oncolytic virus space, a German biotech with a unique approach makes investors reach deeper into their wallets

4 years ago

Atlas backs a longtime Vertex employee’s quest to bring CF success to numerous other diseases

4 years ago

Big Pharma companies join hands with Amazon on new Israel-based AI incubator

4 years ago

Treating autism through the gut? Axial Therapeutics refuels on its exploration of the gut-brain axis

4 years ago

Quiet CinCor Pharma makes some noise with $143M, new trial plans for blood pressure drug

4 years ago

On a quest to challenge Novo Nordisk in obesity, transpacific startup picks up $70M — and a pair of seasoned execs

4 years ago

IPO floodgates open up after summer lull as five more biotechs file for Nasdaq

4 years ago

Supernus expands its portfolio of Parkinson's drugs with a $400M+ buyout

4 years ago

Another three biotechs are set to debut on Nasdaq as combined industry raise tops $14B

4 years ago

OrbiMed's TKI play makes its Nasdaq debut as Theseus prices IPO

4 years ago

With a fresh $75M, Michael Ehlers' latest take on non-viral gene therapy is ready for takeoff

4 years ago

First page Previous page 64 65 666768 69 70 Next page Last page